CRUK
Next Phase of Early Cancer Detection Alliance to Focus on Hereditary Cancers, Disease Interception
Premium
One ACED project is focused on developing biomarkers for the early detection of ovarian cancer, with the goal of commercializing any resulting tests.
Cancer Research UK, Guardant Health Ink Research, Data Sharing Partnership
The collaboration aims to help accelerate the discovery and development of cancer drugs and diagnostics through ongoing and potentially new clinical trials.
Personalis MRD Assays to Support UK's TRACERx ctDNA Monitoring Study
The ongoing lung cancer study, which has employed other assays in the past, will now use the Personalis NeXT Personal platform to monitor for recurrence after surgery.
AstraZeneca, ArcherDx Partner on Minimal Residual Disease Monitoring for Lung Cancer Drug Trials
ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).
The researchers envisage deploying a point-of-care assay based on a fluorescent nanophotonics platform.
Oct 31, 2019
Nov 30, 2018
Jan 20, 2017